semaglutide for liver disease Novo's trial of weight-loss drug shows improvement in fatty FDA grants the first GLP-1

, 2

Furthermore, regulatory hurdles, such as delays in permits or compliance issues, might exacerbate supply shortages

About SELECT SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) was a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for reducing the risk of MACE in people with established CVD with overweight or obesity with no prior history of diabetes

During a water fast, the body has no choice but to burn stored fat for energy, leading to weight loss

Most adverse effects rose sharply at lower doses and plateaued at higher doses

At the higher Wegovy doses, constipation is very common